This collaboration aims to address the critical need for wider availability of comprehensive genomic profiling and liquid biopsy testing across the continent.

The World Health Organization (WHO) reported in February 2023 that Africa faces a significant cancer burden, with an estimated 1.1 million new cases diagnosed annually and roughly 700,000 deaths.

Data suggests this number could rise to nearly one million deaths per year by 2030 without decisive interventions.

Through this partnership, Syndicate Bio will offer cutting-edge liquid biopsy testing, a minimally invasive approach that can benefit patients who currently lack access to traditional diagnostic methods or have to travel outside Africa for testing.

“Our collaboration with SOPHiA GENETICS is focused on enabling the widespread use of precision medicine in oncology across Africa,” said Abasi Ene-Obong, Founder of Syndicate Bio.

“We believe this will significantly improve patient outcomes on the continent.”

Ene-Obong elaborated on the potential of the partnership, stating, “By combining Syndicate Bio’s scientific expertise with SOPHiA GENETICS’ AI-powered technologies and data-driven solutions, we have a unique opportunity to revolutionize cancer care in Africa. This includes non-invasive cancer analysis, predictive genetic testing, and the implementation of effective precision medicine strategies.”

SOPHiA GENETICS recognizes the far-reaching impact of this partnership. The company’s Chief Medical Officer acknowledges that Syndicate Bio’s implementation will not only benefit Africa but also contribute to a comprehensive dataset that will provide valuable insights for shaping the future of global healthcare.

Syndicate Bio, launched in September 2023 by former leaders of African genomics startup 54gene, is dedicated to driving advancements in genomics and precision medicine initiatives, with a primary focus on Africa.

In October 2023, the company signed a Memorandum of Understanding (MoU) with Nigeria’s National Institute of Medical Research (NIMR) to establish a foundation for transformative genomic studies.

This collaboration aims to gain a deeper understanding of diseases prevalent in Nigeria and identify potential targets for drug discovery. NIMR will play a crucial role in ensuring ethical oversight throughout the research process.